International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

High-dose abelacimab bests enoxaparin for VTE prevention

Pearl Toh, 20210821143500

Giving the factor XI inhibitor abelacimab postoperatively was at least similarly effective as, or even superior to, the standard care of enoxaparin in preventing venous thromboembolism (VTE) following total knee arthroplasty, without increasing bleeding risk, according to the ANT-005 TKA trial presented at ISTH 2021.

STASEY confirms safety, efficacy of emicizumab for PwHA with FVIII inhibitors

Audrey Abella, 20210816100000

The STASEY trial, a large, phase IIIb study evaluating a diverse population of persons with haemophilia A (PwHA) with Factor(F)VIII inhibitors, confirms the safety and efficacy profile of the bispecific monoclonal antibody emicizumab that has been demonstrated in the HAVEN trials.

Post-extraction bleeding in patients on NOACs: Does tranexamic acid help?

Audrey Abella, 20210811100000

In patients on non-vitamin K oral anticoagulants (NOACs) who have undergone dental extraction, a 10-percent tranexamic-acid (TXA) mouthwash did not reduce the incidence of oral bleeding following extraction. However, TXA use led to a reduction in the number of total and delayed bleeds, as well as bleeding following multiple extractions, findings from the EXTRACT-NOAC trial have shown.